UK: Lyme Disease - Small Bite, Big Threat

Last Updated: 28 August 2014
Article by Karen Taylor

Most Read Contributor in UK, August 2017

The theme of the World Health Day in April 2014 was vector-borne diseases- 'Small Bite: Big Threat'. For many people this conjured up thoughts of Malaria, Dengue or West Nile Virus but, few people in the UK are aware that the UK's most common vector-borne human infection is Lyme disease.[i]

Although Lyme disease in endemic in the UK few people actually know what it is. Caught early and treated with antibiotics, years of debilitating health problems can be prevented. Yet, many general practitioners (GPs) lack knowledge of the disease and the recommended diagnostic tests lack the sensitivity and specificity to detect early cases or late manifestations of the disease, such as chronic or autoimmune-related infections. As a result the incidence of the disease is seriously underestimated with many cases going undiagnosed or misdiagnosed.

Lyme disease is an infection caused by a family of genetically diverse bacteria called Borrelia burgdorferi. The bacteria are transmitted to humans by ticks, small spider-like insects which live in long grass, woods, and other damp vegetation where they feed on the blood of deer and other mammals. Much like the organism that causes Malaria, the bacteria take different forms throughout their lifecycle, which makes them difficult to detect and leads to a diverse range of symptoms. Symptoms are initially mild and limited to the locality of the bite, but if left untreated chronic Lyme disease often develops which can have devastating, long term effects.

Patients treated with appropriate antibiotics in the early stages of Lyme disease usually recover rapidly and completely. Nevertheless, one of the greatest barriers to effective, early treatment remains GPs lack of awareness of the complexity of the disease, or the diverse symptoms with which patients may present. As a result, too many patients suffer the long-term or chronic impact of Lyme disease and are misdiagnosed with multiple sclerosis, chronic fatigue syndrome and arthritis.

The incidence of Lyme borreliosis has been monitored in England and Wales by the Health Protection Agency (HPA), now part of Public Health England (PHE), since 1996. Since 2010, every microbiology laboratory (including those in the private sector) in England is required to notify all laboratory diagnoses of borreliosis to the Health Protection Agency (now Public Health England). Laboratory-confirmed reports of Lyme disease have risen steadily since surveillance began. In 2011 there were 959 confirmed cases and in 2012, 998[ii]. In acknowledging the significant difficulties in diagnosing Lyme disease, PHE suggest the truer figure is likely to be around 2,000 - 3,000 new cases each year. However, Lyme disease patient groups believe the number to be closer to 15,000 cases a year.[iii]

Factors that may have contributed to the increase include the geographical migration of ticks as a result of successive mild winters, an explosion in the deer population and increased recreational travel to high endemic areas, including walking, trekking, and mountain biking in the UK and abroad.

There are a number of significant challenges in diagnosing Lyme disease:

  • patients may not be aware that they have been infected as ticks are typically invisible to the naked eye and inject a local anaesthetic-like substance so bite goes unnoticed (the longer the tick is in place, the higher the risk of infection)
  • Lyme disease is difficult for GPs to diagnose as the most common, and in some cases only manifestation is erythema migrans (known as the'bull's eye' rash) which appears between three and 30 days after a bite. However around 30 to 40 per cent of patients do not present with a rash (not the 90 per cent cited on the NHS website[iv]), but present with a range of non-specific 'flu-like symptoms, tiredness, headaches, arthralgia (joint pains) and myalgia (muscle aches). Even where there is a rash, this varies in appearance and size (from two to 30 centimeters), expanding over several days or weeks
  • there is no definitive laboratory test for Lyme disease. Since June 2012, the Lyme disease testing service in the UK has been carried out by the Rare and Imported Pathogens Laboratory (RIPL) in Porton Down using a two-tier testing system recommended by American and European authorities comprising: the C6 antigen based enzyme linked immunosorbent assay (ELISA) test; followed by the immuno-blotting (western blotting) test. If the results of both the ELISA test and the Western Blot test are positive, a confident diagnosis of Lyme disease can usually be made.[v]

The manufacturers of both the ELISA and Western Blot tests, however, clearly state that a negative result should NOT be taken as meaning you don't have Lyme disease. Indeed if an initial test is negative, but symptoms persist, there should be a repeat sample 3-4 weeks after the initial test. 

In 2013, PHE launched a series of leaflets to raise awareness of Lyme disease and other tick-borne illnesses among health professionals and the public[vi] and in May this year issued guidelines for referral pathways for patients suspected of having Lyme disease[vii]. This guidance clarifies that the significance of any result, negative or positive, should be interpreted carefully by clinicians in the overall context of the patient's clinical symptoms and exposure risk to ticks. Specifically, patients seen by a GP with an Erythema migrans rash at the time of consultation should be treated with antibiotics indicated for Lyme disease; while patients without a rash but with symptoms suggestive of Lyme disease, and a credible risk of tick exposure, should have serum taken and sent to an NHS laboratory for testing. 

For patients there is currently no vaccine available to prevent Lyme disease. Meanwhile, clinicians have to interpret symptoms which may not match the "classic symptoms" of Lyme and rely on tests which lack sensitivity and specificity. As a result there is some way to go before Lyme's disease can be diagnosed and treated effectively. Work is on-going to equip the GP community to diagnose better and instigate earlier treatment. However, in the absence of an accurate diagnostic test, raising public awareness about risks and prevention and how to identify symptoms early is key if we are to reduce the debilitating effects of this relatively rare, but potentially devastating disease.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.